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Abstract 
Background: The challenging diagnosis and poor prognosis of cholangiocarcinoma require the determination of 
biomarkers. Autoantibodies could be used in the clinic as diagnostic markers for the early detection of tumours. By 
proteomic approaches, several autoantibodies were proposed as potential markers. We tried in this study, to perform 
a serological proteome analysis, using various antigenic substrates, including tumours and human liver.
Methods: Sera from patients (n = 13) and healthy donors (n = 10) were probed on immunoblots performed using 
2‑dimensionally separated proteins from cholangiocarcinoma cell lines (CCLP1 and CCSW1), from the liver of healthy 
subject and interestingly, from tumour and adjacent non‑tumour liver tissues from five patients with cholangiocar‑
cinoma and tested with their corresponding serum. Spots of interest were identified using mass spectrometry and 
classified according gene ontology analysis.
Results: A comparison of the whole immunoblotting patterns given by cholangiocarcinoma sera against those 
obtained with normal control sera enabled the definition of 862 spots. Forty‑five different proteins were further ana‑
lysed, corresponding to (1) spots stained with more than four of 13 (30 %) sera tested with the CCLP1 or the CCSW1 
cell line and with the normal liver, and (2) to spots immunoreactive with at least two of the five sera probed with 
their tumour and non‑tumour counter‑part of cholangiocarcinoma. Immunoreactive proteins with catalytic activity 
as molecular function were detected at rates of 93 and 64 % in liver from healthy subjects or cholangiocarcinoma 
non‑tumour tissues respectively, compared to 43, 33, 33 % in tumour tissues, or CCSW1 and CCLP1 cell lines. A second 
pattern was represented by structural proteins with rates of 7 and 7 % in normal liver or non‑tumour tissues com‑
pared to 14, 33 and 67 % in tumour tissue, CCSW1 or CCLP1 cell lines. Proteins with a binding function were detected 
at rates of 7 % in non‑tumour tissue and 14 % in tumour tissue. Using the extracted tumour tissue, serotransferrin was 
targeted by all cholangiocarcinoma‑related sera.
Conclusions: Immunological patterns depended on the type of antigen substrate used; i.e. tumour versus non 
tumour specimens. Nevertheless, a combination of multiple autoantibodies tested with the most appropriate sub‑
strate might be more sensitive and specific for the diagnosis of cholangiocarcinoma.
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Background
Cholangiocarcinoma (CC) is a primary liver tumour 
which results from the malignant transformation of epi-
thelial cells in any portion of the bile ducts. The incidence 
of CC has increased to 18  % of all liver cancers during 
the past 30–40  years [1]. Its rate of incidence differs as 
a function of geographical region [2]. The prognosis for 
CC is poor and treatment options are very limited. This 
is partly due to its late diagnosis and onset of symptoms; 
because of this, the early diagnosis of CC using specific 
biomarkers remains an important challenge. Antigens 
such as carbohydrate antigens (CA) and carcinoembry-
onic antigen are released from digestive tract tumour 
cells, and their detection in the blood would be a valu-
able tool to diagnose the cancer and monitor its treat-
ment. However, only a few of them appear to be specific 
biomarkers for CC [3, 4]. Moreover, standard techniques 
lack sufficient sensitivity, particularly during the early 
stages of the tumour process, thus hampering their use in 
routine practice.
Differences in protein expression between normal and 
tumour tissues have been studied extensively, includ-
ing in patients with CC [5]. Studies have also targeted 
secreted proteins that are directly accessible in biological 
fluids in the context of CC [6, 7].
Other molecules directly accessible in biological fluids 
are autoantibodies (AAbs), and their presence has been 
reported in sera from patients suffering from a variety 
of malignancies [8]. The origin of the immune response 
in this setting is largely unknown, although it involves 
mutation, incorrect protein folding, over-expression and 
also post translational modifications which cause the 
neo-antigen to be presented to the immune system [8, 9]. 
Because circulating AAbs are produced in large quanti-
ties despite the presence of small amounts of the corre-
sponding antigen, and because of their persistence and 
stability in sera, they may be of considerable diagnostic 
value. In the case of primary liver tumours, and more 
specifically CC, very few studies on AAbs to tumour 
associated antigen (TAA) have been reported.
We therefore focused in this study on identifying 
autoantibodies as biomarkers for the diagnosis of CC, 
using serological proteome analysis (SERPA) which inte-
grates 2D electrophoresis, western blotting and mass 
spectrometry. A similar approach was recently reported 
by Rucksaken et  al. [10]. By using antigenic prepara-
tions from other cholangiocarcinoma cell lines (CCLP1 
and CCSW1), from the liver of healthy humans and 
from tumour and adjacent non-tumour liver tissues 
from patients with cholangiocarcinoma, we were able 
to highlight the heterogeneity of autoantigenic patterns 
reflecting the diversity of the immune response. The 
classification of autoantibody targets according to gene 
ontology analysis enabled the definition of two main pat-
terns which depended on the antigenic extract used, i.e., 
antigens with structural activity if a tumour specimen 
was used for AAbs screening, and antigens with catalytic 
activity if non-tumour specimens were used. In this way, 
it was also possible to identify the most appropriate sub-
strate producing the best sensitivity.
Methods
The design of the study is summarized in Fig. 1. Briefly, 
sera from a pool of ten normal subjects, and from eight 
patients with CC, were tested on two-dimensional immu-
noblots performed using two CC cell lines and human 
liver from healthy subjects. In addition, five CC sera were 
tested on these three substrates and also on immunoblots 
performed using tumour and non-tumour tissue from 
the same CC patients. Spots of interest were identified by 
mass spectrometry (MS), and autoantigens categorised 
according to the Gene Ontology project before further 
classification.
Serum samples and human tissue specimens
All patients gave their informed consent for the collec-
tion of blood and tissue samples. Specimens were con-
served at −80 °C, with approval of the “Committee of the 
Biobanque of Centre Hépato-Biliaire”, managed by the 
“Biological Resource Centre CRB Paris-Sud”. All subjects 
signed a written informed consent form regarding this 
analytical study.
Thirteen serum samples from CC patients followed by 
the Centre Hépato-Biliaire at Hôpital Paul-Brousse, were 
analysed. All the patients fulfilled the international crite-
ria for the diagnosis of CC. Ten pooled sera from healthy 
volunteers were used as controls.
The CC tissues and adjacent non-tumour liver tissues 
used for this study were collected from five CC patients 
who were being treated surgically in our centre. After 
resection, the specimens were rinsed thoroughly in ice-
cold normal saline and stored at −80 °C. Necrotic tissues 
were excluded, and pathological examination of the non-
tumour liver tissues by an expert (CG) confirmed that 
they contained no tumour. Normal liver tissue specimens 
were obtained from patient who had been transplanted 
for amyloid neuropathy.
All liver tissues were homogenized using a Potter-
Elvejhem apparatus, with 10  mM Tris, 50  mM sucrose, 
1  mM EDTA and 1  mM phenylmethyl sulphonide fluo-
ride (PMSF). Homogenates were lysed in buffer with 
50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 % 
triton (v/v), 0.2 % SDS (w/v) and 1 % (v/v) nuclease mix 
(GE Healthcare).
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Fig. 1 Design of the experiment. CC cholangiocarcinoma
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Cell lines
Two human cholangiocarcinoma cell lines, CCSW1 and 
CCLP1, were obtained from the European Cell Cul-
ture Bank, and cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10 % (v/v) 
heat inactivated bovine fœtal serum (BFS), 1  % (v/v) 
minimal essential medium of non-essential amino acids, 
1  mmol/L sodium 2-oxopropanoate, and standard con-
centrations of penicillin plus streptomycin. Whole cell 
proteins were extracted from the cell lines. Cell lysis was 
performed with 20 mM Tris (pH 7.5), 150 mM NaCl, 1 % 
NP40 (Sigma) (v/v), 1× protease inhibitor (Roche, Ger-
many) and 1× phosphatase inhibitor.
Two‑dimensional gel electrophoresis (2‑DE) 
and immunoblotting
Proteins from the lysed homogenates and cell lines were 
precipitated using the 2-D Clean up kit (GE Healthcare) 
and the final protein concentration was measured with 
the 2-D Quant kit (GE Healthcare). Protein samples of 
250  μg for future immunotransfer, or 1  mg for future 
Coomassie blue staining, were mixed with IEF buffer 
(7.5 M urea, 2.2 M thiourea, 4 % (w/v) CHAPS, 0.6 % (v/v) 
immobilised pH gradient (IPG) buffer at pH 3–10, 0.8 % 
(v/v) Destreak® solution (GE Healthcare) and orange G. 
For each sample, the proteins were applied to an immo-
biline Dry Strip® (pH range 3–10, 13 cm; GE Healthcare). 
After overnight rehydration at room temperature, the IEF 
procedure was performed by applying voltage that was 
gradually increased to a maximum of 23,000 V/h.
Each IPG strip was then equilibrated with a solution 
containing 6  M urea, 0.075  M Tris (pH 8.8), 30  % (v/v) 
glycerol, 2 % (w/v) SDS, 2 % (w/v) DTT and pyronine for 
15  min. The strips were equilibrated again by replacing 
DTT with 5 % (w/v) idoacetamide, for a further 15 min. 
The IPG strips were applied to 10  % SDS-PAGE for a 
second dimension protein separation. For subsequent 
immunoblotting, the proteins were transferred to nitro-
cellulose membranes and then blocked for 1  h with 
50 mL blocking buffer: 5 % (w/v) non-fat powdered milk 
in TBS-T (Tris Buffer Saline-Tween 20) PH 7.4, (Tris 1 M 
2 % (w/v), NaCl 0.8 % (w/v), Tween 0.1 % (v/v). The filters 
were then probed with sera diluted 1:2000 in TBS-T, and 
finally incubated with 1:3000 diluted horseradish per-
oxidase-conjugated anti-human immunoglobulin (Bio-
Rad). The proteins were detected by chemiluminescence 
according to the manufacturer’s instructions (ECL Plus™ 
Western Blotting Detection kit, GE Healthcare). After 
transfer, the resulting gels were silver-stained.
The analysis was performed in triplicate. After stand-
ard immunoblotting, the patterns produced by CC sera 
were compared with those given by normal sera using 
scanning and superimposition by means of Adobe 
Photoshop® Software. Spots of interest were defined as 
those which were only stained by CC sera.
The transferred and silver-stained gels and their corre-
sponding immunoblots were also scanned, and after Adobe 
Photoshop® software analysis, the spots of interest were 
localised on the silver-stained gels. These spots were then 
localised together on the corresponding scans of Coomas-
sie blue-stained gels. Immunoreactive spots obtained with 
at least 30 % of CC sera were then identified using MS.
Procedures for protein and peptide preparation
The spots of interest were excised manually. Cysteine 
reduction was performed with 10  mmol/L DTT-
100 mmol/L NH4HCO3 for 45 min at 56 °C, and protein 
alkylation was carried out with 55  mmol/L iodoaceta-
mide-100  mmol/L NH4HCO3 for 30  min in the dark at 
room temperature, the gel pieces being washed succes-
sively with 100  mmol/L NH4HCO3, a 1:1 (by volume) 
mixture of 100 mmol/L NH4HCO3 and acetonitrile, and 
acetonitrile, before being dried again. The gel pieces were 
then rehydrated for 45 min at 4  °C in a digestion buffer 
containing 50 mmol/L NH4HCO3, 5 mmol/L CaCl2, and 
12.5  mg/L trypsin. Peptides generated through proteo-
lytic digestion were extracted by incubation in 10 g/L for-
mic acid for 15 min, which was followed successively by 
two extractions with 10 g/L formic acid-acetonitrile (1:1 
by volume) and acetonitrile. The extracted peptides were 
pooled and dried out in a SpeedVac centrifuge before 
mass spectrometry (MS) analysis.
Mass spectrometry analysis
LC–MS measurements were obtained using a nano 
LC system (Ultimate 3000; Dionex) coupled online to a 
hybrid linear ion trap/Orbitrap® MS (LTQ OrbitrapVe-
los; Thermo Fisher Scientific, Bremen, Germany). One 
microlitre of protein digest was injected onto the nano 
LC system, which contained a C18 trap column (PepMap 
C18, 300 μmID ×  5  mm, 5  μm particle size and 100 Å 
pore size; Dionex) and a 15  cm long analytical column 
(Acclaim pepmap RSLC 75 µm × 15 cm, nanoViper C18, 
2 µm, 100 Å). The peptides were separated according to 
the following gradient: 100 % solvent A (0.1 % formic acid 
in water) for 3 min., 0–55 % solvent B (80 % acetonitrile 
in water with 0.1 % formic acid) for 25 min., 50–90 % sol-
vent B for 1  min and 90  % solvent B for 5  min. A high 
resolution full scan MS was obtained from the Orbitrap® 
(resolution 30,000; AGC 1,000,000), and MS/MS spec-
tra were obtained by CID (collision-induced dissocia-
tion) fragmentation, with an isolation window of 3 Da. A 
data-dependent top 5 (one full MS and 5 MS/MS) was 
obtained with the dynamic exclusion option switched 
on. Spots that were reactive with fewer than 30 % of sera 
were not identified by MS.
Page 5 of 15Mustafa et al. J Transl Med  (2016) 14:17 
Data analysis
The data were analysed using Discoverer Proteome 1.4 
software. The database is a human Swiss-Prot, the mass 
error for the precursor ions (full MS) being less than 
10 ppm. The mass error for ions from the MS/MS spec-
tra is reported to be less than 0.6 Da. Searches for pep-
tide mass are made between 350 and 5000 Da with a time 
retention ranging from 10 to 50 min. A miss cleavage site 
is tolerated. Dynamic modification was enabled for Nter 
acetylation, the oxidation of methionine and histidine, 
and the carbamidomethylation of amino acids, aspartic 
acid and glutamic acid. The static carbamidomethyl mod-
ification of cysteine was enabled. Peptide identifications 
are validated by determining false positives using the 
Target decoy PSM validator. This is high if the false posi-
tive rate (FDR or false Discovery Rate) is less than 1  %, 
low if the FDR is greater than 5  % or average (between 
1 and 5 %). Peptide identification Xcorr were calculated 
by correlating the MS/MS experimental spectrum with 
the theoretical MS/MS spectrum generated by Proteome 
Discoverer 1.4 software.
Detection of anti vimentin and anti actin antibodies 
by immunofluorescence as a validation technique
The presence of anti-vimentin and anti-actin antibodies 
was determined using indirect immunofluorescence on 
monolayers of colchicine-treated Hep2 cells, as described 
elsewhere [11, 12]. Briefly, Hep2 monolayer cells culture 
was home-prepared. This culture performed on slide was 
incubated with colchicine 0.0014 % (w:v) (Sigma) diluted 
in minimum essential medium Eagle (Eurobio), glutamine 
supplemented, during 20  h at 37  °C. After three washes 
with phosphate-buffered saline (PBS), and acetone-fixed, 
the monolayer cells was incubated with sera at the dilution 
of 1/40, in PBS, during 30 min. After PBS washing (3×), 
monolayer cells were revealed using a fluorochrome–
labeled, polyclonal antihuman IgG, IgA, IgM antiserum 
(BioRad Laboratory), 30 min incubated. Vimentin appear 
to be collapsed into thick perinuclear coils if the tested 
serum was positive for anti-vimentin antibodies, and 
a typical pattern of actin cables was strongly stained if 
serum was positive for anti-actin antibodies.
Results
Identification of immunoreactive proteins in cell lines 
from CC patients
CCSW1 cell line
Using the CCSW1 cell line as the antigen, a compari-
son of all the immunoblotting patterns given by CC sera 
against those obtained with normal control sera enabled 
the definition of a total of 172 spots that were only stained 
by CC sera. Nineteen of these 172 spots (11  %) were 
stained with at least one-third (i.e. four sera) of the 13 CC 
sera and eighteen thereafter identified by MS (Additional 
file 1: Table S1; Figs. 2 and 3). They corresponded to ten 
proteins (Table  1): vimentin (four isoforms), which was 
stained by all 13 of the CC sera, prelamin A/C (two iso-
forms) recognized by nine out of 13 sera (69 %), annexin 
A2 (four isoforms) stained by eight sera (62 %), hnRNPL 
recognised by seven sera (54 %), and dihydrolipoyl dehy-
drogenase by six sera (46 %). Six spots were immunoreac-
tive with four (31 %) of the 13 CC sera and corresponded 
to: actin, hnRNP C1/C2, hnRNP K (two isoforms), 
HSP60, protein phosphatase 1 (Table 1).
CCLP1 cell line
Concerning the CCLP1 cell line, 189 spots were stained 
by CC sera only, but only 14 spots corresponding to 
eleven identified proteins were immunoreactive with 
more than four (30  %) out of 13 sera (Additional file  1: 
Table S1; Table 1; Figs. 2, 4). Annexin A2 (two isoforms) 
reacted with nine of the 13 CC sera (69  %), and heat 
shock protein (HSP) β-1 with seven sera (54  %). Actin 
(two isoforms) and annexin A1 (two isoforms) were rec-
ognised by six (46 %) of the 13 CC sera. Fructose-bispho-
sphate aldolase A, lamin-B2, 78  kDa glucose-regulated 
protein (GRP78), and isoform 2 of serine hydroxymeth-
yltransferase were stained by five (38  %) of the 13 CC 
tested sera, whereas gluthathione S-transferase, retinal 
dehydrogenase and vimentin were only recognised by 
four (31 %) of the CC sera.
Immunoreactive protein spots in human liver from healthy 
subject
By comparing the immunoblots of normal liver speci-
mens, 270 spots were specifically stained by CC sera, of 
which 18 were recognized by more than four (31 %) out 
of 13 sera and identified by MS (Additional file 2: Table 
S2; Figs. 2, 5). They corresponded to 16 proteins resulting 
from the existence of isoforms (Table  1). Liver arginase 
1 (two isoforms) and glyceraldehyde-3-phosphate dehy-
drogenase (two isoforms) each reacted with seven (54 %) 
of the 13 CC sera, and 3-ketoacyl-CoA thiolase (two iso-
forms) with six (46 %) sera. Seven proteins correspond-
ing to six spots were stained by five (38 %) of the 13 CC 
sera: aconitate hydratase, bifunctional ATP-dependent 
dihydroxyacetone kinase, electron transfer-flavoprotein 
α, estradiol 17 β dehydrogenase 8, fructose-1.6 biphos-
phatase 1 and fructose-biphosphate aldolase B (both 
identified in the same spot with a high probability), and 
S-methyl-5′ thioadenosine phosphorylase, The remaining 
six spots were stained by four (31 %) of the 13 CC sera: 
acetyl coA acetyl transferase mitochondrial, aldhehyde 
dehydrogenase, carbonic anhydrase 1, Δ(3,5) Δ(2,4) dien-
oyl CoA isomerase, Δ1-pyrroline-5-carboxylate dehydro-
genase and prelamine A/C.
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Fig. 2 Representative example of the immunoblotting pattern displayed by the same serum tested on the different antigenic extracts. a CCLP1 cell 
line; b CCSW1 cell line; c tumour part of cholangiocarcinoma; d non‑tumour part adjacent to the cholangiocarcinoma; e normal liver. Counts with 
arrows correspond to the different immunoreactive spots detected on the corresponding Coomassie‑stained gel (see Figs. 3, 4, 5, 6, 7) and listed in 
Additional file 1: Table S1a, b
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Reactivity patterns of immunoreactive spots in human 
tumour and adjacent non‑tumour tissues
Tumour part of the choliangiocarcinoma
Concerning the five tumour antigen extracts tested by 
immunoblotting with the corresponding patient’s serum 
and then compared against the pattern obtained with 
control sera, widespread immunoreactive spots (n = 118) 
were noted depending on the CC serum tested. Thirty-
nine proteins were identified by MS (Additional file  1: 
Table S1; Figs.  2, 6), but only nine were reactive with 
more than one-third of the sera (Table I). Serotransfer-
rin was identified by 100 % of the five CC sera. Actin was 
stained by four (80  %) of the five sera tested, and ATP 
synthase subunit-α and α-enolase were each stained 
by three (60 %) of the five CC sera. Some proteins were 
immunoreactive with two (40  %) CC sera: annexin A2, 
A4 and A5, proteasome subunit-α type-2 and serum 
albumin.
Non‑tumour tissue adjacent to the cholangioacarcinoma
As for their non-tumour counterparts, a widespread 
immunopattern was noted. A total of 113 spots were 
stained, corresponding to 58 identified proteins, indi-
cating the existence of isoforms (Additional file 2: Table 
S2; Figs. 2, 7). Fourteen proteins were selectively stained 
by more than three (30 %) of the five CC sera (Table 1). 
Fructose-bisphosphate aldolase B was identified by four 
(80  %) of the five patient sera. While HSP60, prelamine 
A/C and serum albumin were reactive with three (60 %) 
of the CC sera. Ten proteins were targets for two (40 %) 
of the five CC sera: 3-ketoacyl-CoA thiolase, α-enolase, 
β-enolase, acetyl-CoA acetyltransferase, ATP synthase 
subunit β, catalase, epoxyde hydrolase, liver arginase, 
liver carboxylesterase 1 and retinal dehydrogenase.
Gene ontology analysis
To obtain a comprehensive view of these different immu-
noreactive proteins, antigens that were recognised by 
more than 30 % of the CC sera were grouped according to 
their elemental activity, the molecular function ontology 
(Table 2), and at the cellular level, to their biological pro-
cess ontology (Table 3). At the cellular level, recognized 
antigens were also grouped according to their protein 
class (Additional file 3: Table S3) and to their molecular 
pathway (Additional file  4: Table S4), as defined by the 
Panther classification (http://www.pantherdb.org).
Non-tumour specimens, i.e., normal liver and non-
tumour tissues adjacent to the CC, contained a high per-
centage of auto-antigenic proteins categorized as catalytic 
activity as a molecular function (92.9 and 64.3 % respec-
tively) (Table 2) when compared to tumour specimens or 
CCSW1 or CCLP1 cell lines (42.9, 33.3 and 33.3 %, respec-
tively), thus explaining the predominance of auto-antigens 
with metabolic process as biological process recognized 
in normal liver (81.3 %) and in non-tumour tissues adja-
cent to the CC (66.7 %) (Table 3) compared to CC tumour 
tissues (42.9 %) and also in CCSW1 and CCLP1 cell lines 
(31.6 and 26.1  %). Proteins classified as oxydoreductase 
or transferase as a molecular pathway displayed the same 
distribution (Additional file 3: Table S3). They constituted 
a large share of the antigens recognised in normal liver 
(at rates of 28.6 and 23.8  % respectively). Oxydoreduc-
tase and transferase were less or not recognised in other 
antigenic substrates. Findings were similar in the pro-
tein pathway group (Additional file 4: Table S4) in which 
enzymes for fructose galactose metabolism and glycolysis 
were detected in normal liver at rates of 12.5 and 25.0 %, 
respectively, and in non-tumour liver specimens at 20.0 
and 40.0 %. Lower rates were found in tumour specimens 
(0 and 9.1 %, respectively), in the CCSW1 cell line (0 and 
0 %) and in the CCLP1 cell line (6.3 and 6.3 %). It is also 
interesting to note that enzymes involved in ATP synthe-
sis (Additional file 4: Table S4) were preferentially recog-
nised in non-tumour tissues adjacent to the CC (20.0 %) 
compared to CC tumour tissues (9.1 %).
As for molecules with structural activity as a molecular 
function (Table 2), they were preferentially recognised in 
the CCSW1 cell line (33.3 %), the CCLP1 cell line (66.7 %) 
and to a lesser extent in tumour specimens (14.3 %). The 
Fig. 3 Coomassie‑blue stained gel of CCSW1 2‑D resolved proteins. 
Proteins immunoreactive with more than 30 % of the 13 CC sera 
compared to controls are indicated by arrows. These immunoreac‑
tive spots are listed in Additional file 1: Table S1. Isoforms of vimentin 
stained by 100 % of CC sera were located as SW7, SW10, SW14, SW19. 
Prelamine A/C (SW2, SW16) was recognized by 69 % of sera, annexin 
A2 (SW3, SW11, SW12, SW18) was a target for 62 % of sera. hnRNP 
L (stained by 54 % of sera) corresponded to SW1. Dihydrolipoyl 
dehydrogenase (46 % of sera) corresponded to SW15. Each of the 
remaining five spots were stained by 31 % of CC sera: actin (SW13), 
hnRNPC1/C2 (SW5), hnRNP K (SW8, SW9), HSP60 (SW17), and protein 
phosphatase 1 (SW6)
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Table 1 Common immunoreactive proteins identified by CC sera in at least one-third of sera with the different antigenic 
extracts used
Proteins Access number CCSW1 CCLP1 Tumour tissue Adjacent non‑
tumour tissue
Normal liver
3‑Ketoacyl‑CoA thiolase P42765 NI NI NI 2/5 (40 %) 6/13 (46 %)
78 kDa glucose regulated protein P11021 NI 5/13 (38 %) NI I NI
α‑Enolase P06733 NI NI 3/5 (60 %) 2/5 (40 %) NI
β‑Enolase P13929 NI NI NI 2/5 (40 %) NI
Acetyl coA acetyl transferase P24752 NI NI NI 2/5 (40 %) 4/13 (31 %)
Aconitate hydratase Q99798 NI NI NI NI 5/13 (38 %)
Actin P60709 4/13 (31 %) 6/13 (46 %) 4/5 (80 %) I NI
Aldehyde dehydrogenase F8W0A9 NI NI NI NI 4/13 (31 %)
Annexin A1 P04083 NI 6/13 (46 %) I NI NI
Annexin A2 P07355 8/13 (62 %) 9/13 (69 %) 2/5 (40 %) I NI
Annexin A4 P09525 NI NI 2/5 (40 %) NI NI
Annexin A5 P08758 NI NI 2/5 (40 %) NI NI
ATP bifunctional dihydroxyacetone kinase Q3LXA3 NI NI NI I 5/13 (38 %)
ATP synthase sub unit α P25705 NI NI 3/5 (60 %) NI NI
ATP synthase sub unit β P06576 NI NI I 2/5 (40 %) NI
Carbonic anhydrase 1 P00915 NI NI I NI 4/13 (31 %)
Catalase P04040 NI NI NI 2/5 (40 %) NI
∆(3,5)‑∆(2,4)‑dienoyl‑CoA isomerase Q13011 NI NI I I 4/13 (31 %)
∆‑1‑pyrroline‑5‑carboxylate dehydrogenase P30038 NI NI NI NI 4/13 (31 %)
Dihydrolipoyl dehydrogenase P09622 6/13 (46 %) NI I I NI
Electron transfer flavoprotein α P13804 NI NI NI NI 5/13 (38 %)
Epoxyde hydrolase P07099 NI NI NI 2/5
(40 %)
NI
Estradiol 17‑β‑dehydrogenase 8 Q92506 NI NI NI NI 5/13 (38 %)
Fructose‑1.6‑biphosphatase 1 P09467 NI NI NI I 5/13 (38 %)
Fructose biphosphate aldolase A P04075 NI 5/13 (38 %) NI NI NI
Fructose biphosphate aldolase B P05062 NI NI NI 4/5 (80 %) 5/13 (38 %)
Glutathione S‑transferase P09211 NI 4/13 (31 %) NI NI NI
Glyceraldehyde‑3‑phosphate dehydrogenase E7EUT4 NI NI I I 7/13 (54 %)
hnRNP C1/C2 G3V4C1 4/13 (31 %) NI NI NI NI
hnRNP K P61978 4/13 (31 %) NI NI NI NI
hnRNP L P14866 7/13 (54 %) NI NI NI NI
HSP1 β1 P04792 NI 7/13 (54 %) I NI NI
HSP 60 P10809 4/13 (31 %) NI NI 3/5 (60 %) NI
Lamin B2 Q03252 NI 5/13 (38 %) NI NI NI
Liver arginase (arginase 1) P05089 NI NI NI 2/5 (40 %) 7/13 (54 %)
Liver carboxyl‑esterase 1 E9PAU8 NI NI NI 2/5 (40 %) NI
Prelamine A/C P02545
P02545‑2
9/13 (69 %) NI I 3/5 (60 %) 4/13 (31 %)
Proteasome su α2 P25787
G3V295
NI NI 2/5 (40 %) NI NI
Protein phosphatase 1 Q15435 4/13 (31 %) NI NI NI NI
Retinal dehydrogenase 1 P00352 NI 4/13 (31 %) I 2/5 (40 %) NI
Serine hydroxymethyltransferase P34896 NI 5/13 (38 %) NI NI NI
Serotransferrin P02787 NI NI 5/5 (100 %) I NI
Serum albumin P02768 NI NI 2/5 (40 %) 3/5 (60 %) NI
S‑methyl‑5′ thioadenosine phosphorylase Q13126 NI NI NI NI 5/13 (38 %)
Vimentin P08670 13/13 (100 %) 4/13 (31 %) I NI NI
NI not identified, I recognized by less than 31 % of CC sera. Access numbers are from the Swiss-Prot database
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rates were lower if the antigens were from non-tumour 
tissues adjacent to the CC (7.1  %) or from normal liver 
(7.1  %). They corresponded to cytoskeletal protein or 
structural protein as protein classes (Additional file  3: 
Table S3) majority found in CC cell lines.
In addition, recognised proteins belonged to the trans-
fer/carrier class (Additional file  3: Table S3) were pre-
dominant in cancer tissue. They represented 20.0 % of the 
AAbs targets tested on CC tumour tissues, compared to 
6.3 % on non-tumour tissues adjacent to the CC.
At least, several members of the annexin family were 
targeted by 40–69  % of CC sera, but only if tumour 
specimens were used for screening (Table 1). They were 
involved in various biological processes, such as a cellu-
lar process for all isoforms, as well as a metabolic process 
for the A1 isoform or a developmental process for the A2 
isoform (Table 3), and as a molecular pathway for the A5 
isoform, the gonadotrophin releasing hormone receptor 
(Additional file 4: Table S4).
Validation of several antigenic targets
Among the various AAbs found, we chose to use a fluo-
rescence technique which, unlike SDS-PAGE, can offer 
access to conformational epitopes and hence detect on 
colchicine-treated Hep2 cells, anti-vimentin antibodies, 
and consequently anti-actin antibodies. A typical immu-
nofluorescence pattern reflecting anti-vimentin was 
observed with eight (61 %) of the 13 CC. Among the six 
sera reacting with actin by immunoblotting, three pro-
duced a typical pattern of actin cable (Additional file  5: 
Figure S1).
Discussion
This study highlights the heterogeneity of autoanti-
gen patterns that reflect the diversity of the immune 
response as a function of the serum tested, the different 
fractions used; thus, as previously, it has underlined the 
specific nature of the immune response in the setting of 
cancer [5]. Our data are in accordance with the recent 
report by Rucksaken [10] which demonstrated that CC 
sera contain AAbs reacting with enolase and heteroge-
neous nuclear ribonucleoprotein L. However, we were 
not able to detect AAbs to ribonuclease/angiotensin 
inhibitor 1 or to heat shock protein 70, as reported by 
Fig. 4 Coomassie‑blue stained gel of CCLP1 2‑D resolved proteins. 
Proteins immunoreactive with more than 30 % of the 13 CC sera 
are highlighted by arrows. These immunoreactive spots are listed 
in Additional file 1: Table S1. Isoforms of annexin A2 were recog‑
nized by 69 % of CC sera and corresponded to spots LP9 and LP14. 
HSP‑β1 (54 % of sera) corresponded to LP12. Isoforms of annexin 
A1 and actin were recognized by 46 % of CC sera and correspond‑
ing spots were LP2 and LP8 (for annexin A1) and LP3 and LP11 (for 
actin). Fructose‑biphosphate aldolase A (LP1), lamin‑B2 (LP4), 78 kDa 
glucose‑regulated protein (LP5) and isoform 2 of serine hydroym‑
ethyltransferase (LP7) were identified by 38 % of CC sera. Each of the 
remaining three spots were stained by only four (31 %) different sera: 
glutathione S‑transferase (LP13), retinal dehydrogenase 1 (LP10) and 
vimentin (LP6)
Fig. 5 Coomassie‑blue stained gel of normal liver 2‑D resolved 
proteins. Proteins immunoreactive with more than 30 % of the 13 
CC sera are indicated by arrows and listed in Additional file 2: Table 
S2. Liver arginase 1 corresponding to arrows NH1 and NH2 and 
glyceraldehyde‑3‑phosphate dehydrogenase (NH6, NH11) were rec‑
ognized by 54 % of 13 CC sera, 3 ketoacyl‑COA thiolase corresponded 
to arrows NH8 and NH9 (46 % of CC sera). Aconitate hydratase 
(NH16), bifunctional ATP‑dependant dihydroxyacetone kinase (NH13), 
electron transfer‑flavoprotein α (NH15), estradiol 17‑β‑dehydrogenase 
8 (NH3), fructose‑1.6 biphosphatase 1 and fructose‑biphosphate 
aldolase B (both identified in the same spot NH10), S‑methyl‑5′ 
thioadenosine phosphorylase (NH7), were each recognized by 38 % 
of the CC sera. Proteins recognized by 31 % of the sera were: acetyl 
CoA acetyl transferase mitochondrial (NH18), aldhehyde dehydroge‑
nase (NH14), carbonic anhydrase 1 (NH5), Δ(3,5) Δ(2,4) dienoyl Coa 
isomerase (NH4), Δ‑1‑pyrroline‑5‑carboxylate dehydrogenase (NH12) 
and prelamine A/C (NH17)
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Fig. 6 Coomassie‑blue stained gels of 2D‑resolved proteins from five tumour‑affected CC livers. Each tumour extract was tested with serum from 
the corresponding patient (C, E, K, P and S). Arrows (CT, ET, KT, PT and ST) indicate the immunoreactive proteins that were only stained by CC sera. 
They are listed in Additional file 1: Table S1. Widespread immunoreactive spots were noted, depending on the CC serum tested. Of the 39 different 
proteins recognized by the CC sera, only nine were reactive with more than one‑third of sera (Table 1). Serotransferrin was identified by 100 % of the 
five CC sera, actin by four (80 %), and ATP synthase subunit‑α and α‑enolase were each stained by three (60 %) of the CC sera. Some proteins were 
immunoreactive with two CC sera (40 %): annexin A2, A4 and A5, proteosome subunit‑α type‑2 and serum albumin
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the same authors. It was nevertheless not surprising to 
observe different immunoreactive patterns being dis-
played by CC sera on the different antigenic extracts 
used, probably due to the specific nature of the cancer 
cells involved or the technique employed. It is postulated 
that autoantibodies in cancer are induced by a break-
down in self-tolerance resulting from over-expression, 
mutations, changes to post-translational modifications 
or the truncation of proteins in a cancer cell [7]. One 
hallmark of cancer is genome instability, which can dif-
fer from one cell to another and of course from normal 
cells to cancer cells [8]. In terms of protein expression 
and modification, choliangocarcinoma cell lines differed 
from the five tumour extracts, which in turn differed 
from each other and also from non-tumour specimens. 
It follows that a protein may be abnormally autoantigenic 
regarding induction of the autoimmune process, and not 
be present in the substrate used for AAb screening.
Secondly, the hepatocytes and cholangiocytes present 
in the liver and cholangiocarcinoma cell lines have dif-
ferent metabolic activities or cellular specializations with 
differencies on the level of expression of antigenic targets.
Thirdly, the 2D electrophoresis technique used during 
our study involved a whole homogenate, implying a bias 
towards abundant proteins.
Added to the previous considerations, some of the 
proteins resolved were found in sufficient quantities to 
be immunoreactive when transferred to a nitrocellu-
lose membrane, whereas others were not; for example, 
nuclear proteins other than histones.
Taken together, these considerations may explain the 
variability of the immunoblotting patterns we noted and 
which differed somewhat from the results obtained by 
Rucksaken [10].
The Gene Ontology classification of autoantigenic tar-
gets as a function of their origin revealed two patterns of 
Table 2 Gene ontology distribution of proteins recognized by CC sera, according to molecular functions
CCSW1 CCLP1 Tumour part Adjacent non‑tumour part Normal liver
Catalytic activity 33.3 % 33.3 % 42.9 % 64.3 % 92.9 %
Structural molecule 33.3 % 66.7 % 14.3 % 7.1 % 7.1 %
Binding 33.3 % – 14.3 % 7.1 % –
Receptor activity – – 14.3 % 7.1 % –
Antioxidant activity – – – 7.1 % –
Transporter activity – – 14.3 % 7.1 % –
Table 3 Gene ontology distribution of proteins recognized by CC sera, according to biological process
CCSW1 CCLP1 Tumour part Adjacent non‑tumour part Normal liver
Metabolic process 31.6 % 26.1 % 42.9 % 66.7 % 81.3 %
Cellular process 21.1 % 17.4 % 7.1 % 6.7 % 6.3 %
Developmental process 21.1 % 17.4 % 14.3 % 6.7 % 6.3 %
Cellular component organization or biogenesis 15.8 % 17.4 % 7.1 % 6.7 % 6.3 %
Localization 10.5 % 4.3 % 28.6 % 13.3 % –
Immune system process – 4.3 % – – –
Multicellular organism process – 4.3 % – – –
Response to stimulus – 8.7 % – – –
(See figure on previous page.) 
Fig. 7 Coomassie‑blue stained gels of 2D‑resolved proteins from five non‑tumour tissues adjacent to the CC livers. Each extract was tested with 
the serum of the corresponding patient (C, E, K, P and S). Arrows (CN, EN, KN, PN and SN) indicate the immunoreactive proteins stained only by CC 
sera. They are listed in Additional file 2: Table S2. As for their non‑tumour counterparts, a widespread immunopattern was noted. Fifty‑eight differ‑
ent proteins were identified. Fourteen proteins were selectively stained by more than three (30 %) of the CC sera (Table 1). Fructose‑bisphosphate 
aldolase B was identified by four (80 %) of the patient sera, HSP60, prelamine A/C and serum albumin by three (60 %). Ten proteins were targets for 
two (40 %) of the CC sera: 3‑ketoacyl‑CoA thiolase, α‑enolase, β‑enolase, acetyl‑CoA acetyltransferase, ATP synthase subunit β, catalase, epoxyde 
hydrolase, liver arginase, liver carboxylesterase 1 and retinal dehydrogenase
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molecular function: catalytic activity or structural activ-
ity (Table 2).
Identified proteins displaying catalytic activity were 
mainly found when liver was used as antigens, includ-
ing normal liver or non-tumour tissues adjacent to the 
CC, and to a lesser extent to tumour-affected part of the 
liver. Hepatocytes are the principal site for carbohydrate 
metabolism, and three of the main targets we found (iden-
tified by at least 40 % of CC sera with the most appropri-
ate antigenic extracts) were enzymes implicated more 
specifically in glycolysis and fructose-galactose metabo-
lism: i.e., alpha-enolase, fructose biphosphate aldolase and 
glyceraldehyde3-phosphate dehydrogenase. Interestingly, 
these three enzymes were found in the secretome of a 
cholangiocarcinoma cell line HuCCA1 [6]. Furthermore, 
enolase and glyceraldehyde3-phosphate dehydrogenase 
were reported as being over-expressed through study of 
the HuCCA1 proteome [5]. Even more interesting, and 
mentioned above, was the report of enolase as an anti-
genic target for CC sera, using substrates other than those 
we used [10]. More generally, by probing a protein array 
with numerous sera from patients with a variety of can-
cers, increased reactivity to glycolytic enzymes has been 
reported [13].
However, these three targets were not all specific to 
CC sera and have been reported (sometimes at a high 
frequency) in liver diseases, including hepatocellular car-
cinoma [14, 15], as well as glyceraldehyde3-phosphate 
dehydrogenase in melanoma [16], enolase in some auto-
immune diseases and infections [17–19] and fructose 
biphosphate aldolase in a case of drug hepatotoxicity 
[20].
Concerning other immunoreactive targets identified 
by fewer CC sera and having catalytic activity, i.e., liver 
arginase and ATP synthase sub-unit β, they have been 
reported in a variety of settings including autoimmune 
diseases [21], Alzheimer’s disease [22], coeliac disease 
[23], idiopathic nephrotic syndrome [24] and also in 
11 % of hepatocellular carcinoma patients [25]. However, 
to our knowledge, ATP synthase sub-unit β has never 
previously been reported as an auto-antigen. Interest-
ingly, ATP synthase is also located at the cell surface and 
may contribute to the development of an acidic micro-
environment in tumour tissues [26]. Its surface location 
allows it to gain access to the immune system, and it has 
been reported as the target of a subset of T-gamma-delta 
lymphocytes [27].
In terms of antigenic targets with structural activity, 
they were essentially found when CC cell lines or tumour 
liver specimens were used as antigens. Three of them 
were identified by more than 50  % of CC sera on the 
most appropriate substrate, i.e., vimentin, prelamine A/C 
and actin. Both actin and members of the intermediate 
filament family have been demonstrated to be strongly 
implicated in tumorogenesis [28–30]. But AAbs to these 
proteins lack specificity as potential biomarkers, because 
they may be detected in various autoimmune disorders 
[31], in liver diseases [32], and in hepatocellular or diges-
tive cancer [32, 33]. However, to our knowledge, AAbs 
to actin have never been reported in the context of liver 
carcinoma. The presence of AAbs to vimentin and actin 
was confirmed using a fluorescence technique that ena-
bled access to a conformational epitope, whereas sero-
logical proteome analysis generates denatured antigens. 
Interestingly, actin has been reported to be found in the 
secretome of HuCCA CC cell lines [6], and its presence 
in a bodily fluid may cause a loss of immune tolerance. 
In this study of Srisomsap [6], annexin was also identi-
fied in the secretome. We also found various isoforms 
of annexin, A1, A2, A4 and A5 as the principal antigenic 
targets for CC sera if they were tested on a tumour sub-
strate (Table 1). Annexin is involved in many cellular pro-
cesses [34], and is implicated in the genesis of numerous 
diseases. Annexin A1 was recently reported to be highly 
expressed in CC, but not in hepatocellular carcinoma 
[35]. The over-expression or post-translational modifica-
tion of annexin A2 has been reported in various cancers, 
such as colorectal, oral and lung cancers [36–40]. How-
ever, AAbs to annexin A2 have also been reported in the 
context of anti-phospholipid syndrome, sometimes in 
association with cancer [41, 42].
One final and interesting observation was the pres-
ence of proteins categorised as transfer/carrier proteins 
and accounting for 20  % of autoantigenic targets in the 
tumour tissues, compared to 6.3  % in the non-tumour 
tissues adjacent to the CC (Additional file  3: Table S3). 
These proteins included serotranferrin, which was rec-
ognised by 100 % of CC sera. Serotansferrin carries iron 
from its absorption sites and delivers the metal to cells 
[43], and may also contribute to stimulating cell prolif-
eration [44]. It was very exciting to note that once again, 
serotransferrin was identified in the secretome of CC cell 
lines [6]. Until now, anti-serotransferrin auto-antibodies 
had been found in 30 % of sera from patients with hepa-
tocellular carcinoma and at a lower rate of 5 % in the con-
text of liver cirrhosis and chronic hepatitis [15].
Conclusion
In order to be used as biomarkers, AAbs need to be both 
highly sensitive and highly specific. However, most of the 
AAbs detected during the present study had previously 
been reported not only in cancers, but also in the con-
text of autoimmune disorders. We therefore cannot con-
clude that AAb alone could be considered as a biomarker, 
in agreement with a previous report [10]. Nevertheless, 
a combination of several AAbs tested on a panel of a 
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significant number of patients, and using the most appro-
priate substrate defined during this study, might be able 
to identify the best biomarkers for CC.
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